The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Nusinersen for the treatment of spinal muscular atrophy
Abstract
Introduction: Spinal muscular atrophy (SMA) is an autosomal recessive degenerative neuromuscular disorder characterized by loss of spinal motor neurons leading to muscle weakness. This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, SpinrazaTM) and describes the exciting journey from early ASO clinical trials to regulatory approval of the first ever known effective treatment for SMA.Areas covered: This article reviews the results of the published open label nusinersen studies in infants and children, and briefly covers the preliminary findings of the recently completed but as yet unpublished nusinersen–sham controlled trials, as well as the presymptomatic nusinersen trial known as Nurture. Clinical use of nusinersen is also reviewed.Expert commentary: Collectively, the studies show improvement in motor function across SMA of all types, including SMA type 3. Best motor response was observed with early treatment; presymptomatic treatment prevented disease manifestations. Nusinersen was found to be safe and well tolerated across all age groups studied. Nusinersen has irrevocably altered the natural history of SMA and allowed for the first time children to transition between SMA types. Nusinersen should be considered as standard of care for the treatment of SMA of all types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Naryshkin, N. A., Weetall, M., Dakka, A., Narasimhan, J., Zhao, X., Feng, Z., Ling, K. K. Y., Karp, G. M., Qi, H., Woll, M. G., et al. (2014) · Science · doi:10.1126/science.1250127 · Cited by 524
Optimality score for the neurologic examination of the infant at 12 and 18 months of age
Haataja, L., Mercuri, E., Regev, R., Cowan, F., Rutherford, M., Dubowitz, V., & Dubowitz, L. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70016-8 · Cited by 387
Meyer, K., Ferraiuolo, L., Schmelzer, L., Braun, L., McGovern, V., Likhite, S., Michels, O., Govoni, A., Fitzgerald, J., Morales, P., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2014.210 · Cited by 286
Cited by
Splicing mutations in human genetic disorders: Examples, detection, and confirmation
Anna, A., & Monika, G. (2018) · Journal of Applied Genetics · doi:10.1007/s13353-018-0444-7 · Cited by 657
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
Bajan, S., & Hutvagner, G. (2020) · Cells · doi:10.3390/cells9010137 · Cited by 393
Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders
Shahryari, A., Saghaeian Jazi, M., Mohammadi, S., Razavi Nikoo, H., Nazari, Z., Hosseini, E. S., Burtscher, I., Mowla, S. J., & Lickert, H. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00868 · Cited by 262
Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Feldman, A. G., Parsons, J. A., Dutmer, C. M., Veerapandiyan, A., Hafberg, E., Maloney, N., & Mack, C. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.05.044 · Cited by 136
Neurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Metadata
- Authors
- Chiriboga, C. A.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2017-09-08
- Volume
- 17
- Issue
- 10
- Pages
- 955-962
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2750790091
- Cited by
- 162
- References
- 3
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nusinersen for the treatment of spinal muscular atrophy. https://app.cochat.ai/papers/10.1080/14737175.2017.1364159
- The paper
- Chiriboga, C. A. (2017). Nusinersen for the treatment of spinal muscular atrophy. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2017.1364159
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.